scispace - formally typeset
M

Maria Dolores Sanchez-Niño

Researcher at Autonomous University of Madrid

Publications -  179
Citations -  36178

Maria Dolores Sanchez-Niño is an academic researcher from Autonomous University of Madrid. The author has contributed to research in topics: Kidney disease & Kidney. The author has an hindex of 50, co-authored 164 publications receiving 27206 citations. Previous affiliations of Maria Dolores Sanchez-Niño include Carlos III Health Institute & Hospital Universitario La Paz.

Papers
More filters
Journal ArticleDOI

Lyso-Gb3 modulates the gut microbiota and decreases butyrate production.

TL;DR: Lyso-Gb3 modifies the biology of gut bacteria, favoring the production of biofilms and altering the composition and short-chain fatty-acid profile of the gut microbiota.
Journal ArticleDOI

Inflammatory Cytokines and Survival Factors from Serum Modulate Tweak-Induced Apoptosis in PC-3 Prostate Cancer Cells

TL;DR: TWEAK/Fn14 pathway activation promotes apoptosis in androgen-independent PC-3 cells under certain culture conditions, and characterization of the therapeutic target potential of TWEAK or Fn14 for human prostate cancer is warranted.
Journal ArticleDOI

Circulating CXCL16 in Diabetic Kidney Disease.

TL;DR: In diabetic kidney disease patients, GFR and serum albumin independently predicted plasma CXCL16 levels, which increased with increasing eGFR category from G1 to G4 and with increasing albuminuria category.
Journal ArticleDOI

Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients

TL;DR: Diabetic patients with CKD have lower circulating 15-epi-LXA4 levels than non-diabetic CKD patients and low dose aspirin for 12 months increased 15-EPi- LXA 4 levels in diabetic patients, which may contribute to the beneficial effects of low doses of aspirin.
Journal ArticleDOI

Chronodisruption: A Poorly Recognized Feature of CKD.

TL;DR: Evidence for chronod isruption in CKD and the impact of chronodisruption on CKD manifestations is discussed, potential chrondisruptors are identified, some of them uremic toxins, and their therapeutic implications are discussed, and current unanswered questions on this topic are discussed.